Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
PsyMed Ventures is a venture capital fund dedicated to transforming the landscape of brain and mental health through innovative technologies. Founded in 2020 and based in San Francisco, the fund supports groundbreaking advancements in neuroscience, including neurotechnology, digital health, and psychedelic medicine. With a commitment to addressing mental health disorders and neurological diseases, PsyMed Ventures aims to foster a new era of personalized and effective treatments.
PsyMed Ventures invests in frontier technologies that aim to revolutionize mental and brain health. Their focus includes neurotechnology, digital health solutions, precision neuroscience, psychedelic medicine, and alternative modalities. By supporting companies that leverage these innovative approaches, PsyMed Ventures seeks to create impactful solutions for mental health challenges.
PsyMed Ventures has invested in notable companies such as Aerska, which focuses on regenerative medicine for Alzheimer's disease; Alto Neuroscience, a precision psychiatry drug development platform; and ATAI Life Sciences, a neuro drug development platform. Other portfolio highlights include Beckley Psytech, Bexson Biomedical, and Journey Clinical, which empower mental health professionals to offer psychedelic-assisted therapy.
To approach PsyMed Ventures, founders should visit their website at psymed.ventures for pitching guidelines and submission details.
PsyMed Ventures has been actively investing in transformative mental health technologies, with their latest investment in Jimini Health at the pre-seed stage in November 2024. They have made a total of 17 investments, focusing heavily on psychedelics and neurotechnology.
PsyMed Ventures invests in Pre Seed, Seed, Seed Plus, Series A, and Series A Plus stages.
Founders can pitch PsyMed Ventures through their website at psymed.ventures.
PsyMed Ventures focuses on healthcare, biotech, AI, digital health, and fintech sectors.
The typical check size ranges from $500K to $1M.
PsyMed Ventures primarily invests in the United States.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.